Flow Cytometry (FC) based Antibody-Cell Binding Evaluation Services
Introduction
Precise characterization of antibody-antigen interactions is fundamental for successful drug discovery and development. Antibodies, central to modern therapeutics, rely on specific and strong binding to target antigens for efficacy and safety. Understanding parameters like affinity, specificity, and cellular uptake is crucial from early discoveries through clinical trials. However, traditional methods often present challenges in throughput, specificity, or physiological relevance. Flow cytometry offers a powerful solution by providing single cell resolution and quantitative data for these critical evaluations.
Fig. 1 Principle of the Flow cytometry-based cellular assay (FCCA) platform.1
Applications of Cell-based Flow Cytometry
Cell-based flow cytometry offers significant advantages, including high throughput and efficiency, high specificity with reduced non-specific binding and ensuring reliable data. It also allows for the analysis of antibody binding and cellular uptake on individual cells, providing unparalleled insights into the heterogeneity of cell populations within complex samples like primary cells or even dissociated tissues. This is critical for understanding target engagement in diverse cellular environments and can reveal subtle differences in binding patterns not detectable by bulk assays.
Flow Cytometry (FC) based Antibody-Cell Binding Evaluation Services
Creative biolabs offers Flow Cytometry (FC) based Antibody-Cell Binding Evaluation Services. We have a clear, professional, and customizable workflow to ensure transparent, efficient project execution and provides the critical data and insights needed to advance your therapeutic programs with confidence. From precise quantification of binding affinities and cellular uptake kinetics to evaluating specificity and functional potential, our comprehensive solutions are designed to accelerate your journey from discovery to market.
Choose Us as Your Partner in Antibody Characterization
Creative Biolabs comprises expert biology specialists with over 20 years of experience, possessing profound scientific knowledge in immunology, pharmacology, and advanced biological assays. This deep expertise allows us to design and execute complex binding and uptake studies. We operate cutting-edge flow cytometry platforms, including advanced multi-laser cytometers and high-throughput automation systems. This ensures superior sensitivity, resolution, and efficiency, enabling the quantification of subtle interactions and the processing of large sample volumes with precision. Ready to unlock deeper insights into your therapeutic antibodies? Contact us for more information and to discuss your project.
FAQs
What types of antibodies and antigens can your FC-based services evaluate?
Our services are highly versatile and can evaluate a wide range of antibodies, including monoclonal antibodies, polyclonal sera, and various isotypes (IgG, IgA, etc.). For antigens, we can assess binding to cell surface-expressed proteins, viral particles, or other cellular targets, utilizing either client-provided cell lines, primary cells, or our custom-engineered stable cell lines expressing specific antigens. We are adept at handling complex and novel targets.
How do your FC-based binding assays compare to traditional ELISA or SPR/Biacore methods?
While ELISA and SPR/Biacore are valuable, our FC-based assays offer unique advantages, especially for cell-surface antigens. Unlike bulk assays, FC provides single cell resolution, allowing for analysis of heterogeneous populations and minimizing background noise. Our platform also uses functionally folded cell-surface expressed antigens, offering greater physiological relevance compared to plate-bound recombinant proteins in ELISA.
Can your services help predict the in vivo behavior of my antibody?
Yes, absolutely. Our FC-based cellular uptake and binding assays are designed to generate quantitative pharmacokinetic (PK) parameters (Km, Vmax, KD, Bmax) that have shown strong correlations with in vivo PK profiles in preclinical models.
Reference
- Sehgal, Al Nasar Ahmed, et al. "Flow Cytometry-Based Measurement of Antibodies Specific for Cell Surface-Expressed Folded SARS-CoV-2 Receptor-Binding Domains." Vaccines 12.4 (2024): 377. Distributed under Open Access license CC BY 4.0. The image was modified by extracting and using Part A of the original image. https://doi.org/10.3390/vaccines12040377
For research use only. Not intended for any clinical use.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
